http://investorshub.advfn.com/boards/read_msg.aspx?message_id=74908449
"how do you spend $50M in RnD in Q1 with absolutely ZERO drugs in clinical development?"
To begin with, you are unaware that Elan has Tysabri in a major p3 trial for SPMS? http://clinicaltrials.gov/ct2/show/NCT01416181?term=natalizumab&rank=1
And here are several more trials - http://www.elan.com/rd/clinical_trials/autoimmune_diseases.asp
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM